Alpha Tau Medical
DRTS
14.25
-0.23
-1.59%
Alpha Tau Medical
US · DRTS
#3046 by market cap
Listed 1970
14.25
-0.23
-1.59%
Live - 5344 symbols - heartbeat 2s ago
· 2026-10-08 08:06
Pre-market
14.25
0.00%
After-hours
14.25
0.00%
- Market cap
- 1.32B
- P/E (TTM)i
- -13.70
- P/Bi
- 29.87
- EPSi
- -0.53
- Div yieldi
- 0.00%
- 52W posi
- 88%
Reader sentiment
Are you bullish or bearish on DRTS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 24.65% -0.05pp
- Institutions
- 80 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Public Company15.85%
Individual/Insider14.91%
Mutual Fund6.47%
Hedge Fund1.87%
Private Company0.28%
Family Office/Trust0.17%
Other60.45%
Top holders as of 2026-05-12
Oramed Pharmaceuticals Inc.
15.67% · 14.47M sh
Uzi Sofer
12.47% · 11.52M sh
Michael Avruch
1.64% · 1.52M sh
Gem Investment Advisors, LLC
1.55% · 1.43M sh
HighTower Advisors, LLC
0.95% · 874.99K sh
Boothbay Fund Management, LLC
0.84% · 773.48K sh
Aquamarine Financial (Cayman) Ltd
0.78% · 721.50K sh
Pier Capital, LLC
0.75% · 691.94K sh
UBS Asset Management
0.70% · 642.26K sh
Yona Keisari
0.55% · 503.49K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
41 filings tracked · 0 buys · 16 sells
| Name | Role | Stake |
|---|---|---|
| Michael Avruch | Director | 1.64% |
| Yona Keisari | Chief Scientific Officer & Member of Scientific Advisory board | 0.55% |
| Raphi Levy | Chief Financial Officer | 0.10% |
| David Milch | Independent Director | 0.10% |
| Samuel Blumenfeld | Independent Director | 0.05% |
| Ruth Alon | Independent Director | -- |
| Alan Adler | Independent Director | -- |
| Nadav Kidron | Director | -- |
| Maya Racine-Netser | Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-20 | Raphi Levy | Chief Financial Officer | Derivative Exercise and Sale | -2,871 | $2.98–15.00 |
| 2026-08-10 | Raphi Levy | Chief Financial Officer | Derivative Exercise and Sale | -17,730 | $2.98–14.00 |
| 2026-07-05 | Raphi Levy | Chief Financial Officer | Derivative Exercise and Sale | -2,270 | $2.98–14.00 |
| 2026-07-01 | Raphi Levy | Chief Financial Officer | Derivative Exercise and Sale | -17,873 | $2.98–13.00 |
| 2026-06-30 | Raphi Levy | Chief Financial Officer | Derivative Exercise and Sale | -2,127 | $2.98–13.02 |
| 2026-06-29 | Raphi Levy | Chief Financial Officer | Open Market Disposition | -20,000 | $12.00 |
| 2026-06-24 | Raphi Levy | Chief Financial Officer | Open Market Disposition | -20,000 | $11.00 |
| 2026-06-22 | Raphi Levy | Chief Financial Officer | Open Market Disposition | -17,500 | $9.47–10.00 |
| 2026-06-02 | Raphi Levy | Chief Financial Officer | Open Market Disposition | -32,500 | $10.76–10.90 |
| 2026-03-17 | Ruth Alon | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Alan Adler | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | David Milch | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Samuel Blumenfeld | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Nadav Kidron | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Maya Racine-Netser | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Raphi Levy | Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Michael Avruch | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-02-24 | Raphi Levy | Chief Financial Officer | Intent to Sell (Form 144) | -10,000 | $7.40 |
| 2026-01-12 | Raphi Levy | Chief Financial Officer | Intent to Sell (Form 144) | -15,000 | $7.09 |
| 2026-01-08 | Raphi Levy | Chief Financial Officer | Intent to Sell (Form 144) | -25,000 | $6.41 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:06:53 · For reference only, not investment advice and not tailored to your situation.